



# ACCP

AMERICAN COLLEGE OF CLINICAL PHARMACOLOGY®  
Advancing Clinical Care through Pharmacology®

## Symposia

MONDAY, SEPTEMBER 16, 2019 | Symposium 10 | 3:30 – 5:00 PM

### *Convergence of Therapeutic Approaches in Oncology & HIV to Target Immune Evasion: Integrating Clinical Pharmacology Lessons Learned*

#### DEVELOPMENT & PATIENT-CENTRIC TRACKS

*Offers both CME & CPE Credit*

UAN #0238-0000-19-010-L01-P

ACPE – 1.5 CONTACT HOURS/KNOWLEDGE-BASED

#### CO-CHAIRS:

**Mariam Ahmed, PhD**, Staff Fellow, US Food & Drug Administration, OMPT/CDER/OTS/OCP

**Daria Stypinski, PhD**, Associate Director, Pfizer Inc, Clinical Pharmacology, Oncology & Global Product Development

#### TARGET AUDIENCE:

This Symposium will be useful for oncology and infectious disease practitioners and researchers.

#### GOALS & OBJECTIVES:

Following the completion of this activity, the learner will be able to:

1. Compare the overlapping mechanisms in HIV and cancer that have made similar treatment strategies possible;
2. Identify approaches from HIV research that are being utilized in oncology and apply clinical pharmacology lessons learned;
3. Identify approaches from oncology that are being evaluated in HIV research and apply clinical pharmacology lessons learned;
4. Explain how the role and skill set required of clinical pharmacologists are being transformed by the emergence of combination therapy approaches and the transition to immune targeting.

---

3:30 – 3:40 PM

#### **Convergence of Therapeutic Approaches in Oncology & HIV to Target Immune Evasion: Integrating Clinical Pharmacology Lessons Learned from Combination Drug Regimens, Checkpoint Inhibitors, CAR-Ts & Other Approaches**

*Mariam Ahmed, PhD, Staff Fellow, US Food & Drug Administration, OMPT/CDER/OTS/OCP*

---

3:40 – 3:55 PM

#### **HIV & Cancer Curative Approaches: Cross-disciplinary Research**

*Steven G. Deeks, MD, Professor of Medicine in Residence, Univ of California San Francisco*

---

3:55 – 4:15 PM

#### **Lessons Learned from HIV Drug Development That Can Be Utilized in Oncology**

*Islam R. Younis, PhD, Director, Astellas Pharma USA Inc, Clinical Pharmacology & Exploratory Development*

---

4:15 – 4:30 PM

#### **Clinical Pharmacology Challenges in the Development of Immuno-oncology Agents**

*Akintunde Bello, PhD, Head, Bristol-Myers Squibb Co, Clinical Pharmacology & Pharmacometrics*

---

4:30 – 4:50 PM

#### **From Antivirals to Immuno-oncology: Changing Expectations in the Era of Combination Therapies & Immune Target Modalities**

*Daria Stypinski, PhD, Associate Director, Pfizer Inc, Clinical Pharmacology, Oncology & Global Product Development*

---

4:50 – 5:00 PM

#### **Faculty Panel Discussion, Questions & Answers, Learner Feedback & Evaluations**